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a b s t r a c t
Background and objective: Additional loading doses and higher maintenance doses (MDs)
have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate
whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1
modify effect of such dose-adjustment strategy.
Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous
coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was
measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off
value of ≥60% was defined as hyporesponsiveness. Polymorphism of two cytochromes
(CYP2C19, CYP2C9) and gene ABCB1 were determined. In patients hyporesponsive to the
initial LD the dose-adjustment was performed using up to 3 additional 600 mg LDs in order to
achieve PRI <60%, and both 150 mg and 75 mg MD were tested at the follow-up.
Results: Patients with at least one CYP2C19*2 allele had higher baseline PRI after the initial
LD (78.2  13.1 vs. 65.3  19.5, P = 0.005). The PRI reduction with additional LD was signifi-
cantly smaller in carriers of the CYP2C19*2 (25.2  15.6 vs. 35.5  16.8, P = 0.025) and similar
trend was observed with subsequent additional LDs. Both MDs were less effective in
presence of CYP2C19*2. Target PRI was, however, more frequently achieved with higher
MD even in presence of CYP2C19*2 (in 70.6% vs. 23.5% of hyporesponders, P = 0.008). No such
differences were observed for other polymorphisms.
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Conclusions: In patients hyporesponsive to a routine clopidogrel doses the potency of
additional LD and higher MD of clopidogrel is compromised by presence of CYP2C19*2
allele. The dose-adjustment strategy is not affected by ABCB1 C3435T or CYP2C9 genotypes.
# 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier
Urban & Partner Sp. z o.o. All rights reserved.
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Dual antiplatelet therapy (DAPT) as a combination of aspirin and
a P2Y12-receptor antagonist reduces thrombotic complications
in patients with acute coronary syndrome (ACS) or undergoing
percutaneous coronary intervention (PCI), and it is a recom-
mended treatment in current clinical guidelines [1]. For the last
decade as a standard DAPT was the combination of aspirin
and clopidogrel until newer generation more effective
P2Y12-receptor antagonists (prasugrel, ticagrelor) became avail-
able which provide more rapid, potent and reliable
P2Y12-receptor inhibition [1–3]. Although prasugrel and ticagre-
lor reduced the risk of cardiovascular death, myocardial
infarction or stroke compared to clopidogrel in patients with
ACS, the concerns of higher bleeding risk coupled with an
increase in costs remain important shortcomings with the
newer agents [4,5]. These considerations have encouraged the
further investigation in a search for more personalized approach
in each individual patient.
The pharmacodynamic response to clopidogrel varies
among patients and standard doses of clopidogrel achieve
suboptimal platelet inhibition. Hence, the ‘‘high on-treatment
platelet reactivity’’ (HTPR) or hyporesponsiveness has been
described in up to 50% of patients [2,6]. Numerous individual
studies as well as several meta-analyses have demonstrated
that HTPR is strongly associated with cardiovascular death,
myocardial infarction and stent thrombosis (ST) in patients
undergoing PCI [7].
Routine or platelet function testing-guided administration of
higher or repeated clopidogrel loading doses (LDs) and higher
maintenance doses (MDs) have failed to overcome hyporespon-
siveness in a significant proportion of patients and yielded
unsatisfactory long-term clinical results [8–15]. Genetic variants
of CYP2C19 and ABCB1 genes have been associated with
hyporesponsiveness and cardiovascular events among patients
on treatment with clopidogrel [16]. Variations of these genes
affect the rate of metabolism of clopidogrel that is pro-drug, and
production of the active metabolite [16,17]. There are limiteddata
if and how these polymorphisms affect the efficacy of tailored
additional LDs and MDs used in hyporesponsive patients [18].
We aimed to investigate whether genetic polymorphisms
of CYP2C19, ABCB1 and CYP2C9 modify effect of (i) additional
600 mg LDs of clopidogrel and (ii) higher MD (150 mg vs. 75 mg)
in order to overcome hyporesponsiveness.
2. Materials and methods
In a prospective single-center study we included patients
undergoing PCI with a drug eluting stent (DES) who received LDof clopidogrel according to the guidelines, namely, 300 mg or
600 mg for patients with scheduled or acute PCI, respectively
[19–21]. The enrollment period was between September 2010
and December 2012. The following exclusion criteria were
applied: expected noncompliance to therapy, congestive heart
failure New York Heart Association functional class IV, bleeding
or history of bleeding diathesis, platelet count <100  109/L, oral
anticoagulant therapy, chronic liver disease (cirrhosis, hepati-
tis) or serum bilirubin >2 mg/dL, hemorrhagic stroke or stroke of
unspecified origin, malignancy or other concurrent severe
illness with expected survival <1 year, contraindication to dual
antiplatelet therapy as deemed by the treating physician. The
protocol was approved by the local ethics committee and was
according to the Declaration of Helsinki. Patients were included
after two informed consents were obtained separately for each
of two study components: treatment to clopidogrel and genetic
investigation. Among initially included 118 patients only
94 patients fully adhered to the study design. One patient
withdrew consent to the genetic analysis during the study
therefore we report data on 93 patients. The remaining
24 patients were excluded during the study due to the following
deviations from the protocol: incorrect use of clopidogrel doses
(n = 12), treating physician changed clopidogrel to another
antiplatelet drug (n = 8), patients refused a follow-up visit
(n = 4). Minority of the patients (n = 18, 19.4%) underwent
emergent or urgent PCI due to an acute coronary syndrome.
2.1. Blood samples
Blood samples for VASP phosphorylation analyses were drawn
by atraumatic venipuncture of the antecubital vein. The first
sample was taken after the PCI with DES on the second day
after the routine LD. The subsequent samples were taken
between 12 and 24 h after each additional LD, and at least 3 h
after the last MD at the follow-up. Blood was collected into a
vacutainer containing 3.8% trisodium citrate and filled to
capacity. The vacutainer was inverted 3–5 times for gentle
mixing and taken to the laboratory.
2.2. Platelet reactivity measurements
The VASP phosphorylation analysis was performed within 24 h
of blood collection by an experienced investigator using Platelet
VASP kits (PLT VASP/P2Y12, Biocytex, Marseille, France)
according to the manufacturer's instructions [22]. A citrated
blood sample was incubated with prostaglandin E1 (PGE1) and
ADP 10 mmol/l for 10 min and fixed with paraformaldehyde,
after which the platelets were permeabilized with a nonionic
detergent. Analyses were performed on a Cytomics FC – 500 flow
cytometer (Beckman Coulter, France), the platelet population
was identified from its forward and side scatter distribution, and
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PRI) was calculated from the mean fluorescence intensity (MFI)
of samples incubated with PGE1 or PGE1 and ADP according to
the formula: VASP PRI = [(MFIc PGE1  MFIc (PGE1 + ADP))/MFIc
PGE1]  100. According to the first VASP test patients were
classified into responders or hyporesponders (VASP PRI <60% or
≥60%, respectively) to clopidogrel.
2.3. Treatment protocol
Hyporesponders received up to three additional LDs (each
600 mg), and the VASP PRI was repeated at least 12 h after each
administration until a target VASP PRI (<60%) was reached. If
these three additional LDs were unable to decrease the VASP
PRI to <60%, patients were defined as resistant and were
switched to ticagrelor. Hyporesponders received MD of 150 mg
once daily for 30 days followed by MD of 75 mg till the end of
12 months in total. Responders received MD of 75 mg once
daily for 12 months. Both groups were tested for VASP PRI on
day 40 while on 75 mg. Hyporesponders had additional
analysis of VASP PRI on day 10 while on MD of 150 mg.
2.4. Genetic polymorphisms
2.4.1. DNA isolation
DNA was acquired through the Latvian Genome Data Base
(LGDB), a government funded biobank. DNA was extractedTable 1 – Baseline demographic, clinical, angiographic and bio
All patients (n = 93) 
Age, years 63.0 (9.7) 
Men, n (%) 49 (52.7) 
BMI, kg/m2 29.7 (4.6) 
Previous myocardial infarction, n (%) 33 (35.5) 
History of CABG, n (%) 2 (2.2) 
Cardiovascular risk factors
Current smoker, n (%) 11 (11.8) 
Diabetes mellitus, n (%) 28 (30.1) 
Hypertension, n (%) 83 (89.2) 
Laboratory evaluation
WBC, 109/L 7.8 (2.2) 
Hemoglobin, g/L 1.4 (0.2) 
Platelets, 103/L 225.9 (51.4) 
Fibrinogen, g/L 3.4 (1.3) 
Creatinine, mmol/L 83.2 (23.9) 
GFR, mL/min 63.2 (23.9) 
TC, mmol/L 4.5 (1.4) 
HDL-C, mmol/L 1.2 (0.4) 
LDL-C, mmol/L 2.6 (1.1) 
TG, mmol/L 1.4 (0.9) 
Angiography and intervention
Number of treated vessels 1.1 (0.2) 
Number of stents per patient 1.4 (0.6) 
Number of DES per patient 1.2 (0.4) 
GP IIb/IIIa inhibitor use, n (%) 44 (47.3) 
Values are mean (standard deviation) unless otherwise stated.
BMI, body mass index; WBC, white blood cells; TC, total cholesterol; HDL-C
cholesterol; TG, triglycerides; GFR, glomerular filtration rate; DES, drug-efrom white blood cells by standard phenol-chloroform proto-
col, DNA concentration measured by Nanodrop ND1000
spectrophotometer (Thermo Scientific, Wilmington, Delaware,
USA) and subsequently stored at 70 8C [23].
2.4.2. SNP genotyping
DNA samples were aliquoted from storage tubes into 96-well
polymerase chain reaction (PCR) plates using a Tecan with
Freedom Evo system (Tecan, Mannedorf, Switzerland) dispos-
able filter tips. DNA concentration was normalized to 7 ng/mL.
Genotyping was carried out using an Applied Biosystems
TaqMan SNP Genotyping Assay with a modified protocol
using 4.75 mL TaqMan Genotyping Mix (Life Technologies,
Carlsbad, California, USA), 0.25 mL SNP genotyping assay
ID C_25626674_20 (Life Technologies) and 5 mL Millipore
H2O (Millipore, Bedford, MA) on a Viia7 Real-Time PCR system
(Life Technologies).All7 SNPs had dbSNP identification numbers:
rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3), rs56337013
(CYP2C19*5), rs12248560 (CYP2C19*17), rs1799853 (CYP2C9*2),
rs1057910 (CYP2C9*3) and rs1045642 (ABCB1 C3435T), respective-
ly. Probe and primer sequences are available on request. Variants
were called using ViiA7 Software v1.2.1 (Life Technologies) [24].
2.5. Statistical analysis
Continuous variables were compared with Student t test (for
two groups) or ANOVA (for more than 2 groups). Categoricallogic characteristics (n = 94).
Responders (n = 26) Hyporesponders (n = 67) P
63.6 (10.9) 63.6 (10.9) 0.719
13 (50.0) 36 (53.7) 0.819
27.1 (2.8) 30.7 (4.8) 0.001
8 (30.8) 25 (37.3) 0.554
1 (3.8) 1 (1.5) 0.647
2 (7.7) 9 (13.6) 0.579
9 (34.6) 19 (28.4) 0.555
24 (92.3) 59 (89.4) 0.797
7.5 (1.5) 7.9 (2.4) 0.415
1.4 (1.1) 1.4 (2.2) 0.540
239.1 (48.8) 220.6 (51.8) 0.115
3.2 (0.8) 3.4 (1.4) 0.516
80.2 (16.2) 84.4 (26.3) 0.451
55.8 (15.3) 66.0 (26.0) 0.072
4.3 (1.1) 4.6 (1.4) 0.315
1.3 (0.4) 1.2 (0.4) 0.654
2.5 (0.9) 2.7 (1.2) 0.437
1.2 (0.7) 1.5 (1.0) 0.175
1.1 (0.3) 1.0 (0.2) 0.542
1.4 (0.6) 1.4 (0.6) 0.981
1.2 (0.4) 1.2 (0.5) 0.946
12 (46.2) 32 (48.5) 0.840
, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
luting stent; GP, glycoprotein.
Fig. 2 – Effect of each additional loading dose (600 mg) in
hyporesponders on platelet reactivity index (PRI) (A). Effect
of 150-mg and 75-mg maintenance doses at 10 and 40
days, respectively, in hyporesponders (n = 65, two resistant
patients switched to ticagrelor excluded) and effect of
75-mg maintenance dose in responders (n = 26) (B).
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test as appropriate. Repeated measurements were compared
with paired t-test and McNemar test for continuous and
categorical data, respectively. Correspondence of genotype
distribution to Hardy–Weinberg equilibrium was tested with
chi-square goodness of fit test. When gene dose effect was
analyzed, Spearman correlation was used. Two-sided P value
<0.05 was regarded as statistically significant. All statistical




Baseline characteristics of the study population are summa-
rized in Table 1. There were no differences between respond-
ers and hyporesponders regarding demographic and clinical
data, except for BMI (P = 0.001; Table 1).
3.2. Platelet parameters
The mean PRI after the initial dose of clopidogrel (PRI1) was
68.4  18.9%. We observed large inter-individual variability in
clopidogrel responsiveness, with PRI ranging from 8% to 94%
(Fig. 1). The majority of patients (n = 67, 72.0%) were hypor-
esponsive (PRI1 ≥ 60%) to initial clopidogrel LD. Fig. 2A
summarizes the effect of each additional clopidogrel LD on
PRI in hyporesponders. The target PRI was attained with one,
two and three additional LDs in 43 (66.2%), 13 (20.0%) and 9
(13.8%) patients, respectively.
Two patients (2.2%) were identified as resistant to clopido-
grel as the three additional LDs were unable to achieve PRI
below 60%. Both participants responded, however, to ticagrelor
180 mg (Fig. 3), which reduced PRI statistically significantly
compared to PRI4 (12.0  1.4 vs. 73.0  4.2, P = 0.042).Fig. 1 – Baseline vasodilator-stimulated phosphoprotein
platelet reactivity index (PRI) after the initial loading dose
of clopidogrel (n = 93).Effect of the two MDs (150 mg and 75 mg) on PRI was
investigated during follow-up on day 10 and 40, respectively, in
hyporesponders, and on day 40 (75 mg MD) in responders
(Fig. 2B). Only 8 (12.3%) hyporesponders had PRI ≥60% while on
150 mg MD on day 10 compared to 32 (49.2%) patients while on
75 mg MD on day 40 (P = 0.005). On day 40, fewer patients in
responders group had PRI ≥60% (n = 2, 7.7%) compared to
hyporesponders (n = 33, 50.8%) while on 75 mg MD (P < 0.001).
The mean VASP PRI for elective cases who received 300 mg
LD of clopidogrel was not significantly lower compared to acuteFig. 3 – Platelet reactivity index (PRI) in clopidogrel-resistant
patients and the effect of ticagrelor.
Table 2 – Genotype distributions and allele frequencies of all investigated genetic variations.
Polymorphism Genotype Patients, n (%) Pa Allele Allele frequency
CYP2C19
CYP2C19*2 GG (wt/wt) 71 (76.3) 0.686 G 0.876 (163)
(G681A/rs4244285)b AG (wt/*2) 21 (22.6) A 0.124 (23)
AA (*2/*2) 1 (1.1)
CYP2C19*3 GG (wt/wt) 92 (98.9) 0.958 G 0.995 (185)
(G636A/rs4986893) AG (wt/*3) 1 (1.1) A 0.005 (1)
CYP2C19*5 CC (wt/wt) 90 (100.0) NA C 1.000 (90)
(C1297T/rs56337013) CT (wt/*5)
CYP2C19*17 CC (wt/wt) 36 (38.7) 0.523 C 0.634 (118)
(C806T/rs12248560) CT (wt/*17) 46 (49.5) T 0.366 (68)
TT (*17/*17) 11 (11.8)
CYP2C9
CYP2C9*2 CC (wt/wt) 86 (92.5) 0.706 C 0.962 (179)
(C430T/rs1799853) CT (wt/*2) 7 (7.5) T 0.038 (7)
CYP2C9*3 AA (wt/wt) 79 (84.9) 0.433 A 0.925 (172)
(A1075C/rs1057910) CA (wt/*3) 14 (15.1) C 0.075 (14)
ABCB1
ABCB1 CC 17 (18.2) 0.410 C 0.452 (84)
(C3435T/rs1045642) CT 50 (53.8) T 0.548 (102)
TT 26 (28.0)
NA, not applicable; wt, wild-type; SNP, single-nucleotide polymorphism.
a Hardy–Weinberg equilibrium.
b According to National Center for Biotechnology Information.
Table 3 – Repartition of genetic polymorphisms of
CYP2C19, CYP2C9 and ABCB1 according to response to







wt/wt 65.3 (19.5) 0.016 48/71 (67.6) 0.220
wt/*2 77.7 (13.2) 18/21 (85.7)
*2/*2 89.0 (–) 1/1 (100)
CYP2C19*3
wt/wt 68.2 (19.0) 0.472 66/92 (71.7) 1.000
wt/*3 82.0 (–) 1/1 (100)
CYP2C19*17
wt/wt 73.0 (15.0) 0.140 29/36 (80.6) 0.307
wt/*17 64.7 (20.7) 30/46 (65.2)
*17/*17 68.7 (20.8) 8/11 (72.7)
CYP2C9*2
wt/wt 68.6 (18.9) 0.687 63/86 (73.3) 0.361
wt/*2 65.6 (20.6) 4/7 (57.1)
CYP2C9*3
wt/wt 69.1 (17.7) 0.385 58/79 (73.4) 0.488
wt/*3 64.3 (25.2) 9/14 (64.3)
ABCB1
CC 67.0 (22.5) 0.379 11/17 (64.7) 0.683
CT 66.5 (18.7) 36/50 (72.0)
TT 72.8 (16.9) 20/26 (76.9)
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74.0  8.0, P = 0.285).
3.3. Genotyping results
No deviations from the Hardy–Weinberg equilibrium were
detected. Genotype distribution and allele frequencies of the
genetic variations studied are presented in Table 2. For the
CYP2C19 genotype, one patient was homozygote for the *2
mutant allele of CYP2C19 (1.1%), 21 (22.6%) were heterozygotes
and 71 (76.3%) were homozygotes for the wild-type allele.
3.4. Relationship of genotypes with PRI
Table 3 summarizes platelet reactivity after the first routine
dose (PRI1) by genotypes. Carriers of the CYP2C19*2 allele (wt/*2
and *2/*2) had significantly higher PRI1 compared with patients
homozygous for CYP2C19 wild-type genotype (78.2  13.1 vs.
65.3  19.5, P = 0.005).
Platelet activity remained higher in carriers of the
CYP2C19*2 allele (wt/*2 and *2/*2) after the first additional LD
(PRI2) compared with homozygotes of CYP2C19 wild-type
genotype (57.0  19.1 vs. 40.8  21.5, P = 0.006) (Fig. 4). The
absolute decrease of mean PRI following the first additional LD
(PRI1–PRI2) was significantly smaller in carriers vs. noncarriers
of *2 (25.2  15.6 vs. 35.5  16.8, P = 0.025) (Table 4).
The platelet reactivity with two different MDs of clopidogrel
in the whole group and responders/non-responders stratified by
the genotypes is summarized in Table 5. Both MDs were less
effective in the presence of CYP2C19*2. Among hyporesponders,
carriers of CYP2C19*2 (wt/*2 and *2/*2) had significantly higher
PRI on day 10 while on the 150 mg MD (53.3  12.1 vs. 40.3  13.5,
P = 0.001) and on day 40 while on the 75 mg MD (65.5  10.4 vs.
56.3  14.5, P = 0.020) compared with homozygous for CYP2C19wild type genotype. In the whole study group carriers of
CYP2C19 *2 had higher PRI with 75 mg MD (63.1  11.3 vs. 50.3
 17.1, P = 0.002).
Target PRI <60% was achieved in 70.6% vs. 93.8% of patients
with 150 mg MD (P = 0.024), and 23.5% vs. 58.3% with 75 mg MD
(P = 0.014) in carriers and non-carriers, respectively. The success
Fig. 4 – Platelet reactivity after clopidogrel each loading dose
depending on genetic polymorphism of CYP2C19*2 (n = 93).
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both in carriers and non-carriers of CYP2C19*2 (P = 0.008 and
P < 0.001, respectively).
Patients with CYP2C19*17 allele (wt/*17 and *17/*17) had
lower PRI1 compared with homozygous for CYP2C19 wild-type
genotype (65.4  20.6 vs. 73.0  15.0, P = 0.060) (Table 3).
Carriers of both gain-of-function allele of the CYP2C19*17
(*17/*17) had similar PRI1 compared with patients with one
gain-of-function allele or homozygotes of the wild-type allele
(wt/*17 and wt/wt) (68.3  18.8 vs. 68.7  20.8, P = 0.947). No
other polymorphism in recessive or dominant model had
significant association with baseline or any other PRI.
The two clopidogrel-resistant patients had the following
genotypes: (i) patient A, CYP2C9*3 wt/wt, CYP2C9*2 wt/wt,
CYP2C19*2 wt/*2, CYP2C19*3 wt/wt, CYP2C19*5 wt/wt,
CYP2C19*17 wt/*17, ABCB1 C/T, and (ii) patient B, CYP2C9*
3wt/wt, CYP2C9*2 wt/wt, CYP2C19*2 wt/*2, CYP2C19*3 wt/wt,
CYP2C19*5 wt/wt, CYP2C19*17 wt/wt, ABCB1 T/T.Table 4 – Influence of the first additional loading dose of
clopidogrel on the platelet reactivity according to the
CYP2C19, CYP2C9 and ABCB1 genotypes.
Genotype n PRI1–PRI2, % (SD) P
CYP2C19*2
wt/wt 48 35.5 (16.8) 0.025
wt/*2 and *2/*2 19 25.2 (15.6)
CYP2C19*17
wt/wt 29 31.7 (16.2) 0.705
wt/*17 and *17/*17 38 33.3 (17.8)
CYP2C19*3
wt/wt 66 32.8 (17.1) 0.392
wt/*3 1 18.0 (–)
CYP2C9*2
wt/wt 63 32.3 (17.1) 0.659
wt/*2 4 36.3 (17.4)
CYP2C9*3
wt/wt 58 32.9 (17.5) 0.691
wt/*3 9 30.4 (14.3)
ABCB1
CC 17 32.9 (17.1) 0.719
CT/TT 76 30.8 (17.3)4. Discussion
Our study confirms the previous reports that the patients
carrying the loss-of-function CYP2C19*2 allele have signifi-
cantly higher PRI following an initial LD of clopidogrel than
wild-type homozygotes [2]. In addition, we have demonstrated
that PRI reduction (PRI1–PRI2) after the first additional 600 mg
LD of clopidogrel is significantly smaller in CYP2C19*2 allele
carriers. Similar trend was observed after the second and
subsequent loading doses, which was non-significant pre-
sumably due to smaller number of patients requiring more
than one additional LD.
Previous studies reporting on the impact of ABCB1 C3435T
genotypes on clopidogrel treatment efficacy have provided
inconsistent results. For instance, in the PLATO trial the ABCB1
3435CC high-expression genotype was associated with in-
creased risk of cardiovascular death, myocardial infarction,
and stroke in the clopidogrel arm of the study [17], whereas in
the TRITON-TIMI 38 trial, the highest event rates were
observed in carriers of the opposite (3435TT) ABCB1 genotype
[25]. Importantly, in a meta-analysis by Su et al. T allele was
associated with increased early and long-term risk of major
cardiovascular events with 300 mg LD, but not with 600 mg LD
[26]. Our data go in line with this analysis as we observed
similar, although nonsignificant, trend of higher PRI values
with TT genotype after the initial LD.
Of note, in none of the studies included in the meta-
analysis dose adjustment guided by platelet function testing
was performed. Such study, however, has been recently
published by Bonello et al. [18], in which they found that
CYP2C19*2, but neither PON1 nor ABCB1 genotype, was
associated with HTPR after the initial LD, while only ABCB1
was responsible for the failure of the additional LD strategy.
Since there were only two patients in whom dose-adjustment
failed in our study, the statistical comparison with the other
patients was not feasible. Both clopidogrel-resistant patients,
however, were carriers of T allele (heterozygote and homozy-
gote), as well as heterozygotes for CYP2C19*2, which supports
the notion that both alleles may be involved in resistance, but
not the only responsible factors. Importantly, both patients
had pronounced response to ticagrelor, underscoring the
advantage of the newer drug.
There are several differences between our study and the
study reported by Bonello et al. [18]. In our study the sample
was smaller, most of patients underwent scheduled PCI and
thus received 300 mg initial LD in line with the current
guidelines [1], as well as the target PRI was <60%. In contrast,
Bonello et al. included only patients with acute coronary
syndrome receiving 600 mg of initial LD, and set the target PRI
<50%. Importantly, first blood sample for VASP analysis was
taken after the PCI in our study as opposed to before the
intervention in the study by Bonello et al. One may argue that
mechanical injury itself may augment platelet reactivity and
confound the findings. It remains unclear, however, to what
extent, if any, the different findings regarding effects of ABCB1
C3435T can be attributed to the above-mentioned factors.
Altogether our data suggest, that CYP2C19*2 has much
stronger impact on PRI reduction with additional LD than
ABCB1 T allele.




n Hyporesponders (n = 65)a All patients (n = 91)a
75 mg 150 mg 75 mg 75 mg
CYP2C19*2
wt/wt 23 37.7 (15.4) 48 40.3 (13.5) 56.3  14.5 50.3 (17.1)
wt/*2 3 49.7 (5.1) 16 51.9 (10.9) 64.7  10.2 62.3 (11.0)
*2/*2 – 1 76.0 (–) 78.0 (–) 78.0 (–)
P = 0.198 P = 0.001 P = 0.043 P = 0.006
CYP2C19*3
wt/wt 21 38.8 (15.0) 56 43.1 (14.6) 59.5 (13.7) 52.8 (16.6)
wt/*3 5 40.0 (16.9) 9 47.8 (11.8) 53.7 (15.8) 81.0 (–)
P = 0.877 P = 0.362 P = 0.247 P = 0.095
CYP2C19*17
wt/wt 7 32.1 (8.0) 28 45.5 (15.1) 58.7 (11.8) 3.4 (15.4)
wt/*17 16 41.6 (17.7) 29 42.1 (14.6) 59.0 (16.2) 52.8 (18.6)
*17/*17 3 41.7 (7.5) 8 43.3 (9.7) 57.9 (14.3) 53.5 (14.6)
P = 0.379 P = 0.665 P = 0.982 P = 0.984
CYP2C9*2
wt/wt 23 39.8 (15.8) 61 43.8 (13.8) 59.0 (14.3) 53.7 (17.0)
wt/*2 3 33.3 (2.5) 4 42.0 (23.0) 55.0 (9.6) 45.7 (13.5)
P = 0.495 P = 0.805 P = 0.588 P = 0.228
CYP2C9*3
wt/wt 21 38.8 (15.0) 56 43.1 (14.6) 59.5 (13.7) 53.9 (16.8)
wt/*3 5 40.0 (16.9) 9 47.8 (11.8) 53.7 (15.8) 48.8 (17.0)
P = 0.877 P = 0.362 P = 0.247 P = 0.299
ABCB1
C/C 6 49.5 (18.3) 11 45.6 (12.0) 62.1 (13.6) 57.7 (16.1)
C/T 6 34.2 (12.0) 35 42.1 (15.1) 58.1 (14.0) 51.3 (17.2)
T/T 14 39.8 (14.9) 19 46.2 (14.2) 57.9 (14.8) 53.6 (16.5)
P = 0.109 P = 0.595 P = 0.688 P = 0.404
a Two clopidogrel-resistant patients switched to ticagrelor were excluded.
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 9 – 2 7 25In our view there is a discrepancy between the high
prevalence of patients not reaching target PRI <50% reported
in literature (from 16% to 50%) and much lower frequency of
stent thrombosis rates observed in the randomized studies
during the first year (<1%) [9,27,28]. We therefore attempted to
test the safety of PRI <60% as a less conservative target for the
dose-adjustment strategy. The one-year clinical follow-up data
will be reported separately.
Despite the raised cut-off value, the prevalence of hypor-
esponders with PRI ≥60% after the initial LD was higher than
expected (72.0%). One may speculate that DES is more
frequently chosen in diabetics and complicated lesions, hence
higher atherosclerosis burden, which in turn may be associat-
ed with higher platelet reactivity and lead to a selection bias.
Use of 300 mg LD may be another factor contributing to higher
PRI, although in our sample elective cases receiving 300 mg LD
had lower PRI than acute patients receiving 600 mg LD.
We observed that CYP2C19*2 carriers had higher PRI with
both 75 mg MD and 150 mg MD of clopidogrel. In these patients
150 mg MD was significantly more effective than 75 mg MD to
maintain target PRI <60%. We did not find significant interaction
of ABCB1 genotype and efficacy of either MD. These findings
confirm previous reports [10,29,30] that 150 mg MD may be
preferred to 75 mg in carriers of CYP2C19*2, although no benefit
of such strategy has been shown to improve clinical outcomes.In our view this finding additionally supports importance of
CYP2C19*2 over ABCB1 since effect of LD is short-lasting.
No other polymorphisms (CYP2C19*3, CYP2C19*5, CYP2C
19*17, CYP2C9*2, CYP2C9*3 and ABCB1 C3435T) were found to
have clearly significant interaction with LDs or MDs. It should be
noted, that minor alleles of these polymorphisms are rare, and
therefore are unlikely to have as high clinical significance as
CYP2C19*2 if the type 2 statistical error was present. Besides the
smaller sample size, another limitation of the study is the
heterogeneity of study group as about one fifth of the patients
had ACS and received 600 mg initial LD.
The advantage of the present study is the use of the platelet
VASP test (PLT-VASP), which is highly specific to P2Y12
inhibition. This method has other significant logistical
advantages including: (i) aspirin and other medications such
as GPIIb/IIIa antagonists do not interfere with the results, (ii)
analysis can be performed within 48 h from the collection of
the blood, (iii) the samples can be stored at room temperature,
(iv) only a single full citrate tube is required.
The results of the present study are of potential interest to
help define a therapeutic strategy to improve platelet reactivity
inhibition in hyporesponders. Integrated approach of testing
both presence of CYP2C19*2 and degree of platelet reactivity may
be superior to platelet function testing alone in order to achieve
the most optimal P2Y12 inhibition in each individual patient.
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 9 – 2 7265. Conclusions
In patients hyporesponsive to a routine clopidogrel doses the
potency of additional LD and higher MD of clopidogrel is
compromised by presence of CYP2C19*2 allele. The dose-
adjustment strategy is not affected by ABCB1 C3435T or
CYP2C9 genotypes.
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